早期反应可预测骨髓瘤的预后。 - Suppr | 超能文献

Early response predicts myeloma outcome.

作者信息

Palumbo Antonio

机构信息

Azienda Ospedaliero-Universitaria San Giovanni Battista.

出版信息

Blood. 2010 Mar 25;115(12):2332-3. doi: 10.1182/blood-2010-02-268730.

DOI:10.1182/blood-2010-02-268730

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Early response predicts myeloma outcome.

Blood. 2010 Mar 25;115(12):2332-3. doi: 10.1182/blood-2010-02-268730.

2

Evaluation of the serum free light chain (sFLC) analysis in prediction of response in symptomatic multiple myeloma patients: rapid profound reduction in involved FLC predicts achievement of VGPR.

Eur J Haematol. 2014 Nov;93(5):407-13. doi: 10.1111/ejh.12376. Epub 2014 Jun 14.

3

Unsustained complete response of less than 24 months after autologous stem cell transplantation predicts aggressive myeloma with short survival.

Hematol Oncol. 2014 Dec;32(4):205-11. doi: 10.1002/hon.2131. Epub 2014 Jan 29.

4

Early chemosensitivity to VAD regimen predicts a favorable outcome after autologous stem cell transplantation in multiple myeloma.

Haematologica. 2002 Jul;87(7):779-81.

5

Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.

Hum Pathol. 2012 Jun;43(6):858-64. doi: 10.1016/j.humpath.2011.07.013. Epub 2011 Nov 1.

6

Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma.

J Cancer. 2020 Jan 1;11(5):1182-1194. doi: 10.7150/jca.37313. eCollection 2020.

7

A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.

Haematologica. 2004 May;89(5):552-6.

8

Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role.

Leukemia. 2018 Nov;32(11):2427-2434. doi: 10.1038/s41375-018-0072-6. Epub 2018 Feb 23.

9

MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy.

Genes Chromosomes Cancer. 2018 Aug;57(8):420-429. doi: 10.1002/gcc.2.

10

Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models.

Mol Cancer Ther. 2016 May;15(5):1132-44. doi: 10.1158/1535-7163.MCT-15-0730. Epub 2016 Mar 3.

引用本文的文献

1

Early response to bortezomib combined chemotherapy can help predict survival in patients with multiple myeloma who are ineligible for stem cell transplantation.

J Korean Med Sci. 2013 Jan;28(1):80-6. doi: 10.3346/jkms.2013.28.1.80. Epub 2013 Jan 8.